专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

WO2004012686A2 NITROSATED AND/OR NITROSYLATED URSODEOXYCHOLIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE 审中-公开
标题翻译：硝化和/或硝化的乌索二氧甲酸化合物，组合物和使用方法
公开(公告)号：WO2004012686A2
公开(公告)日：2004-02-12
申请号：PCT/US2003/024689
申请日：2003-08-06
申请人： NITROMED, INC. , GARVEY, David, S. , IYENGAR, Radha
发明人： GARVEY, David, S. , IYENGAR, Radha
IPC分类号： A61K
CPC分类号： C07J41/0055
摘要： The invention describes nitrosated and/or nitrosylated ursodeoxycholic acid compounds, or an amide or sulfate conjugate thereof, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated ursodeoxycholic acid compounds, or an amide or sulfate conjugate thereof, or pharmaceutically acceptable salts thereof, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one ursodeoxycholic acid compound, or an made or sulfate conjugate thereof, or pharmaceutically acceptable salts thereof, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one ursodeoxycholic acid compound, that is optionally nitrosated and/or nitrosylated, and, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating and/or preventing portal hypertension, liver diseases, reflux, gastritis, inflammatory conditions of the gastrointestinal tract, coronary heart diseases, neurological or cognitive conditions or for lowering cholesterol levels.
摘要翻译：本发明描述了亚硝基化和/或亚硝基化的熊去氧胆酸化合物或其酰胺或硫酸盐缀合物或其药学上可接受的盐，以及包含至少一种亚硝基化和/或亚硝基化熊去氧胆酸化合物的新组合物，或其酰胺或硫酸酯缀合物或其药学上可接受的盐，任选地，至少一种捐赠，转移或释放一氧化氮的化合物，刺激一氧化氮的内源性合成，提高内源性内皮水平的内皮衍生的松弛因子，或是一氧化氮合酶，和/或至少一种治疗剂。本发明还提供包含至少一种熊去氧胆酸化合物或其制成或硫酸盐缀合物或其药学上可接受的盐和至少一种捐赠，转移或释放一氧化氮的化合物的新型组合物，其提高内源性内皮水平的内皮衍生的松弛因子刺激一氧化氮的内源性合成或者是一氧化氮合酶和/或至少一种治疗剂的底物。本发明还提供了新颖的试剂盒，其包含至少一种熊去氧胆酸化合物，其任选被亚硝化和/或亚硝基化，并且任选地包含至少一种一氧化氮供体和/或至少一种治疗剂。本发明还提供治疗和/或预防门静脉高压症，肝脏疾病，反流，胃炎，胃肠道炎症，冠心病，神经或认知疾病或降低胆固醇水平的方法。

72. 发明申请

WO2004012659A2 NITROSATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE 审中-公开
标题翻译：硝基脲泵抑制剂，组合物和使用方法
公开(公告)号：WO2004012659A2
公开(公告)日：2004-02-12
申请号：PCT/US2003/023963
申请日：2003-08-01
申请人： NITROMED, INC. , FANG, Xinqin , GARVEY, David, S. , LETTS, Gordon, L.
发明人： FANG, Xinqin , GARVEY, David, S. , LETTS, Gordon, L.
IPC分类号： A61K
CPC分类号： C07D401/12
摘要： The invention describes novel nitrosated proton pump inhibitor compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated proton pump inhibitor compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated proton pump inhibitor compound, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated proton pump inhibitor compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating gastrointestinal disorders; facilitating ulcer healing; decreasing the recurrence of ulcers; improving gastroprotective properties, anti- Helicobacter pylori properties or antacid properties of proton pump inhibitors; decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds; treating bacterial infections and/or viral infections.
摘要翻译：本发明描述了新的亚硝化质子泵抑制剂化合物及其药学上可接受的盐，以及包含至少一种亚硝化质子泵抑制剂化合物和任选的至少一种捐赠，转移或释放一氧化氮的化合物，刺激内源性硝酸合成的新型组合物氧化物，提高内源性内源性水平的内源性松弛因子，或者是一氧化氮合酶的底物和/或至少一种治疗剂。本发明还提供了包含至少一种亚硝化质子泵抑制剂化合物和至少一种捐赠，转移或释放一氧化氮的化合物，提高内源性内皮衍生的松弛因子水平，刺激一氧化氮的内源性合成或是底物的新型组合物用于一氧化氮合酶和/或至少一种治疗剂。本发明还提供了包含至少一种亚硝化质子泵抑制剂化合物和任选的至少一种一氧化氮供体和/或至少一种治疗剂的新型试剂盒。本发明还提供了治疗胃肠道疾病的方法; 促进溃疡愈合; 减少溃疡复发; 改善胃保护性质，抗幽门螺旋杆菌性质或质子泵抑制剂的抗酸性; 降低或减少与使用非甾体抗炎化合物相关的胃肠道毒性; 治疗细菌感染和/或病毒感染。

73. 发明申请

WO2004002420A2 OXIME AND/OR HYDRAZONE CONTAINING NITROSATED AND/OR NITROSYLATED CYCLOOXIGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE 审中-公开
标题翻译：含有硝化和/或硝化的环己糖合酶-2选择性抑制剂的肟和/或腙，组合物和使用方法
公开(公告)号：WO2004002420A2
公开(公告)日：2004-01-08
申请号：PCT/US0320421
申请日：2003-06-30
申请人： NITROMED INC , GARVEY DAVID S , RANATUNGE RAMANI R , RICHARDSON STEWART K
发明人： GARVEY DAVID S , RANATUNGE RAMANI R , RICHARDSON STEWART K
IPC分类号： A61K31/415 , A61K45/00 , A61P1/00 , A61P1/04 , A61P7/00 , A61P7/02 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/02 , A61P11/06 , A61P13/00 , A61P13/02 , A61P13/12 , A61P15/00 , A61P17/00 , A61P19/02 , A61P25/00 , A61P25/02 , A61P25/28 , A61P27/02 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/08 , A61P43/00 , C07D231/12 , A61K
CPC分类号： C07D231/12
摘要： The invention describes novel cyclooxygenase 2(COX-2) selective inhibitors having at least one oxime group or hydrazone group and novel compositions comprising at least one cyclooxigenase 2(COX-2) selective inhibitor having at least one oxime group or hydrazone group, and optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor having at least one oxime group or hydrazone group, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxigenase 2 selective inhibitors of the invention having at least one oxime group or hydrazone group can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxigenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.
摘要翻译：本发明描述了具有至少一个肟基团或腙基团的新型环氧合酶2（COX-2）选择性抑制剂和包含至少一种具有至少一个肟基团或腙基团的环氧合酶2（COX-2）选择性抑制剂的新型组合物，，至少一种捐赠，转移或释放一氧化氮的化合物，刺激一氧化氮的内源性合成，提高内源性内皮细胞衍生的松弛因子水平，或者是一氧化氮合酶的底物，和/或至少一种治疗剂。本发明还提供包含至少一种COX-2选择性抑制剂的新型试剂盒，所述抑制剂具有至少一个任选亚硝化和/或亚硝基化的肟基团或腙基团，和任选地至少一个一氧化氮供体，和/或任选地至少一种治疗剂。具有至少一个肟基团或腙基团的本发明的新型环氧合酶2选择性抑制剂可以任选被亚硝化和/或亚硝基化。本发明还提供治疗炎症，疼痛和发热的方法; 用于治疗和/或改善COX-2选择性抑制剂的胃肠道特性; 用于促进伤口愈合; 用于治疗和/或预防肾和/或呼吸毒性; 用于治疗和/或预防由环氧合酶-2水平升高引起的其他疾病; 并用于改善COX-2选择性抑制剂的心血管特征。

74. 发明申请

WO2003086282A3 NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE 审中-公开
公开(公告)号：WO2003086282A3
公开(公告)日：2003-10-23
申请号：PCT/US2003/010562
申请日：2003-04-07
申请人： NITROMED, INC. , FANG, Xinqin , GARVEY, David, S. , GASTON, Ricky, D. , LIN, Chia-En , RANATUNGA, Ramani, R. , RICHARDSON, Stewart, K. , WANG, Tiansheng , WANG, Weiheng , WEY, Shiow-Jyi
发明人： FANG, Xinqin , GARVEY, David, S. , GASTON, Ricky, D. , LIN, Chia-En , RANATUNGA, Ramani, R. , RICHARDSON, Stewart, K. , WANG, Tiansheng , WANG, Weiheng , WEY, Shiow-Jyi
IPC分类号： C07D235/00
摘要： The invention describes novel nitric oxide donors and novel compositions comprising at least one nitric oxide donor. The invention also provides novel compositions comprising at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for the inhibition of platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative, vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering the nitric oxide donor optionally in combination with at least one therapeutic agent. The invention also provides methods for treating inflammation, pain, fever, gastrointestinal disorders, respiratory disorders and sexual dysfunctions. The nitric oxide donors donate, transfer or release nitric oxide, and/or elevate endogenous levels of endothelium-derived relaxing factor, and/or stimulate endogenous synthesis of nitric oxide and/or are substrates for nitric oxide synthase and are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions. The therapeutic agent can optionally be substituted with at least one NO and/or NO 2 group (i.e., nitrosylated and/or nitrosated). The invention also provides novel compositions and kits comprising at least one nitric oxide donor and/or at least one therapeutic agent.

75. 发明申请

WO0185013A3 INFRARED THERMOGRAPHY AND METHODS OF USE 审中-公开
标题翻译：红外热像仪及其使用方法
公开(公告)号：WO0185013A3
公开(公告)日：2002-08-22
申请号：PCT/US0114699
申请日：2001-05-08
申请人： NITROMED INC , MAREK PRZEMYSLAW A , TROCHA ANDRZEJ M
发明人： MAREK PRZEMYSLAW A , TROCHA ANDRZEJ M
IPC分类号： A61B5/00 , A61K31/42 , A61K49/00 , A61B6/00
CPC分类号： A61B5/4368 , A61B5/015 , A61K49/0004 , Y10S514/929
摘要： The present invention describes rapid non-invasive methods for measuring vasodilation or changes in blood flow in a patient following administration of at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent. The method comprises administration of at least one compound to the patient followed by monitoring the temperature change of an area of interest using infrared thermography.
摘要翻译：本发明描述了在施用至少一种捐赠，转移或释放一氧化氮的化合物之后测量患者血管舒张或血流变化的快速非侵入性方法，提高内源性内皮衍生的松弛因子水平，刺激内源性合成一氧化氮或一氧化氮合酶的底物和/或至少一种血管活性剂。该方法包括向患者施用至少一种化合物，然后使用红外热成像法监测感兴趣区域的温度变化。

76. 发明申请

WO0012076A9 NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE 审中-公开
标题翻译：硝基和硝基磷酸酯酶抑制剂，组合物和使用方法
公开(公告)号：WO0012076A9
公开(公告)日：2000-08-17
申请号：PCT/US9920024
申请日：1999-09-01
申请人： NITROMED INC , GARVEY DAVID S , SAENZ DE TEJADA INIGO , EARL RICHARD A , KHANAPURE SUBHASH P
发明人： GARVEY DAVID S , SAENZ DE TEJADA INIGO , EARL RICHARD A , KHANAPURE SUBHASH P
IPC分类号： C07D473/30 , A61K31/198 , A61K31/4015 , A61K31/4188 , A61K31/4375 , A61K31/4439 , A61K31/444 , A61K31/445 , A61K31/454 , A61K31/4709 , A61K31/472 , A61K31/4745 , A61K31/4985 , A61K31/50 , A61K31/501 , A61K31/517 , A61K31/519 , A61K31/52 , A61K31/522 , A61K31/7004 , A61K31/7084 , A61K38/00 , A61K45/00 , A61P1/00 , A61P1/18 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/02 , A61P13/08 , A61P13/12 , A61P15/00 , A61P15/10 , A61P25/28 , A61P27/16 , A61P29/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07D207/12 , C07D213/89 , C07D215/227 , C07D237/04 , C07D239/95 , C07D277/22 , C07D279/04 , C07D401/02 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D403/10 , C07D405/14 , C07D471/04 , C07D471/14 , C07D487/04 , C07D487/14 , A61K31/165 , A61K31/38 , A61K31/40 , A61K31/415 , A61K31/425 , A61K31/44 , A61K31/47 , A61K31/505 , C07D207/24 , C07D207/46 , C07D211/72 , C07D211/84 , C07D213/72 , C07D213/75 , C07D213/81 , C07D213/83 , C07D233/28 , C07D233/30 , C07D233/32 , C07D233/38 , C07D279/06 , C07D295/00 , C07D401/00 , C07D417/00 , C07D487/00
CPC分类号： C07D487/04 , C07D405/14
摘要： Disclosed are nitrosated and/or nitrosylated compounds of formulae (I)-(XIX) which are phosphodiesterase inhibitors and compositions comprising them. The invention also provides methods for treating or preventing sexual dysfunctions in males and females and also diseases induced by cGMP.
摘要翻译：公开了作为磷酸二酯酶抑制剂的式（I） - （XIX）的亚硝基化和/或亚硝化化合物及其组成。本发明还提供了治疗或预防男性和女性性功能障碍的方法以及由cGMP引起的疾病。

77. 发明申请

WO1997034871A1 NITROSATED AND NITROSYLATED COMPOUNDS AND COMPOSITIONS AND THEIR USE FOR TREATING RESPIRATORY DISORDERS 审中-公开
标题翻译：硝基和硝基化合物及其组合物及其用于治疗呼吸道疾病的用途
公开(公告)号：WO1997034871A1
公开(公告)日：1997-09-25
申请号：PCT/US1997004319
申请日：1997-03-19
申请人： NITROMED, INC. , GARVEY, David, S. , LETTS, L., Gordon , RENFROE, H., Burt , RICHARDSON, Stewart, K.
发明人： NITROMED, INC.
IPC分类号： C07D211/18
CPC分类号： C07D451/06 , C07C313/36 , C07D311/22 , C07D451/10 , C07D471/04 , C07J5/00 , C07J7/00 , C07J31/00 , C07J71/00 , C07J71/0031
摘要： Disclosed are (i) compounds of a steroid, a beta -agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO2 group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, beta -agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO2 moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO ) or nitroxyl (NO ), or as the neutral species, nitric oxide (NO) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.
摘要翻译：公开的是（i）直接或间接连接到NO或NO 2基团或刺激内源性产生NO或EDRF的组的类固醇，β-激动剂，抗胆碱能药，肥大细胞稳定剂和磷酸二酯酶（PDE）抑制剂的化合物体内; （ii）类固醇，β-激动剂，抗胆碱能药物，肥大细胞稳定剂和PDE抑制剂的组合物，其可任选地被至少一个NO或NO 2部分或刺激体内NO或EDRF内源性产生的基团取代;以及化合物捐赠，转移或释放一氧化氮作为带电物质，即亚硝酸盐（NO +）或硝酰基（NO - ），或作为中性物质，一氧化氮（NO）或刺激内源性产生NO或 EDRF体内; 和（iii）用于预防和/或治疗呼吸系统疾病。

78. 发明申请

WO2007075542A3 NITRIC OXIDE ENHANCING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE 审中-公开
标题翻译：氮氧化物增强吡咯化合物，组合物和使用方法
公开(公告)号：WO2007075542A3
公开(公告)日：2009-04-16
申请号：PCT/US2006048194
申请日：2006-12-19
申请人： NITROMED INC , GARVEY DAVID S
发明人： GARVEY DAVID S
IPC分类号： A01N43/04 , A61K31/70
CPC分类号： A61K31/421 , A61K31/537
摘要： The invention provides novel compositions and kits comprising at least one nitric oxide enhancing pyruvate compound, or a pharmaceutically acceptable salt thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (1) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating reperfusion injury following ischemia; and/or (m) preserving tissues, organs, organ parts and/or limbs. The nitric oxide enhancing pyruvate compounds comprise at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group.
摘要翻译：本发明提供了包含至少一种一氧化氮增强丙酮酸化合物或其药学上可接受的盐，和任选的至少一种一氧化氮增强化合物和/或至少一种治疗剂的新型组合物和试剂盒。本发明还提供了（a）治疗心血管疾病的方法; （b）治疗血管性疾病; （c）治疗糖尿病; （d）治疗由氧化应激引起的疾病; （e）治疗内皮功能障碍; （f）治疗由内皮功能障碍引起的疾病; （g）治疗肝硬化; （h）治疗先兆子痫; （j）治疗骨质疏松症; （k）治疗肾病; （1）治疗外周血管疾病; （m）治疗门静脉高压; （n）局部缺血后再灌注损伤; 和/或（m）保存组织，器官，器官部分和/或肢体。一氧化氮增强丙酮酸化合物包含至少一种杂环一氧化氮供体基团和/或至少一种氮氧化物基团。

79. 发明申请

WO2007120555A3 ASSESSMENT OF HEART FAILURE RISK USING GENETIC ASSESSMENT OF G-PROTEIN BETA-3 SUBUNIT POLYMORPHISM 审中-公开
标题翻译：使用G蛋白β-3亚基多态性的遗传评估评估心脏失效风险
公开(公告)号：WO2007120555A3
公开(公告)日：2008-11-27
申请号：PCT/US2007008426
申请日：2007-04-04
申请人： NITROMED INC , UNIV PITTSBURGH , WORCEL MANUEL , SABOLINSKI MICHAEL , TAM SANG W , MCNAMARA DENNIS M
发明人： WORCEL MANUEL , SABOLINSKI MICHAEL , TAM SANG W , MCNAMARA DENNIS M
IPC分类号： A01N43/58 , A01N33/02 , A01N33/18 , A01N33/24 , A01N43/08 , A01N43/60 , A01N45/00 , A61K31/04 , A61K31/135 , A61K31/34 , A61K31/495 , A61K31/50 , A61K31/56
CPC分类号： A61K31/21 , A61K31/34 , A61K31/502 , A61K45/06 , A61K2300/00
摘要： The invention provides methods for treating various indications and diseases in a patient in need thereof, wherein the patient has a C825T polymorphism in the G protein beta3 subunit (GNB3), comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.
摘要翻译：本发明提供了在有需要的患者中治疗各种适应症和疾病的方法，其中所述患者在G蛋白β3亚基（GNB3）中具有C825T多态性，其包括给予所述患者（i）至少一种抗氧化剂化合物或药学上其可接受的盐; （ii）至少一种一氧化氮增强化合物; 和（iii）任选的治疗心血管疾病的最佳治疗方法。在一个实施方案中，抗氧化剂是肼azine嗪化合物或其药学上可接受的盐，一氧化氮增强化合物是硝酸异山梨酯和/或硝酸异山梨酯。

80. 发明申请

WO2007097951A3 METHODS USING HYDRALAZINE COMPOUNDS AND ISOSORBIDE DINITRATE OR ISOSORBIDE MONONITRATE 审中-公开
公开(公告)号：WO2007097951A3
公开(公告)日：2007-08-30
申请号：PCT/US2007/003825
申请日：2007-02-12
申请人： NITROMED, INC. , LOBERG, Michael, D.
发明人： LOBERG, Michael, D.
IPC分类号： A61K38/00
摘要： The invention provides methods for (a) treating decompensated heart failure; (b) treating compensated heart failure; (c) treating renovascular diseases and (d) treating end-stage renal diseases in a patient in need thereof comprising administering an effective amount of (i) at least one hydralazine compound or a pharmaceutically acceptable salt thereof, (ii) isosorbide dinitrate and/or isosorbide mononitrate, and (iii) optionally at least one compound selected from the group consisting of an angiotensin converting enzyme inhibitor, a β-adrenergic antagonist, an angiotensin II antagonist, an aldosterone antagonist, a cardiac glycoside (digitalis) and a diuretic compound or a combination of two or more thereof. The hydralazine compound may be hydralazine hydrochloride.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式